In addition, we confirmed the potency of E7130 monotherapy for reducing α-SMA-positive CAFs in this model and the other types of SCCHN xenografts (Supplementary Fig. S5e–h). This evidence concerns the gene ACTA1 and head and neck squamous cell carcinoma.